AIM ImmunoTech presents Phase 1a trial data for faridoxorubicin

Avacta Therapeutics announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin to be presented at the 2025 European Society of Medical Oncology Annual Congress in Berlin, Germany. Faridoxorubicin treatment data demonstrate favorable safety and tolerability across both the every three weeks and every two weeks dosing regimens. The trial data also demonstrate a robust reduction in toxicities associated with conventional doxorubicin therapy, with preliminary efficacy in patients with salivary gland cancers and soft tissue sarcomas. Cardiac safety data in patients treated above the standard cumulative dose demonstrate no severe toxicity observed either in treatment stage or in follow up and no severe cardiac adverse events were reported in the trial, regardless of the cumulative dose level.